| Abstract: | Background: There has been evidence that methamphetamine (METH) use disorder is heritable and probably highly polygenic. Shared genetic factors may explain the high comorbidity between METH use and other psychiatric disorders. Previous studies also suggest possible shared etiological mechanisms between METH-associated psychosis and primary psychosis. We aimed to examine whether METH use disorders are genetically correlated with other psychiatric disorders using a polygenic risk score (PRS) approach. Methods: A total of 1,227 patients with MA use were recruited. Genome-wide single nucleotide polymorphism (SNP) genotyping, demographic, and clinical information were obtained. Healthy controls were 91,582 individuals, who self-reported no history of psychiatric and neurologic disorders, with genome-wide genotypic data available from Taiwan Biobank. We used PRS-CSx to calculate PRS for schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), alcohol dependence (AD), and cigarette smoking (CS), and tested their associations with METH use and METH-associated psychosis. Results: METH use was significantly associated with PRS of MDD (P= 9.85E-08), ADHD (P= 1.44E-08), AD (P= 1.14E-17), and CS (P= 1.56E-17). METH-associated psychosis was significantly associated with PRS of SCZ (P=3.02E-12). Discussion: METH use was genetically correlated with MDD, ADHD, AD, and CS, while METH-associated psychosis was genetically correlated with SCZ. |
